Trial Outcomes & Findings for Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin (NCT NCT03158532)
NCT ID: NCT03158532
Last Updated: 2024-12-09
Results Overview
Incidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular doppler ultrasound
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
2040 participants
Primary outcome timeframe
2 to 24 hours after procedure
Results posted on
2024-12-09
Participant Flow
Participant milestones
| Measure |
Placebo I/Placebo II
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I/Placebo II
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Placebo I /Nitroglycerin II
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I /Nitroglycerin II
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
510
|
510
|
510
|
510
|
|
Overall Study
COMPLETED
|
510
|
510
|
510
|
510
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Placebo I/Placebo II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I/Placebo II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Placebo I /Nitroglycerin II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I /Nitroglycerin II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Total
n=2040 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
61.52 years
STANDARD_DEVIATION 10.35 • n=510 Participants
|
62.06 years
STANDARD_DEVIATION 10.29 • n=510 Participants
|
61.52 years
STANDARD_DEVIATION 10.35 • n=510 Participants
|
62.06 years
STANDARD_DEVIATION 10.29 • n=510 Participants
|
61.79 years
STANDARD_DEVIATION 10.32 • n=2040 Participants
|
|
Sex: Female, Male
Female
|
188 Participants
n=510 Participants
|
199 Participants
n=510 Participants
|
199 Participants
n=510 Participants
|
188 Participants
n=510 Participants
|
774 Participants
n=2040 Participants
|
|
Sex: Female, Male
Male
|
322 Participants
n=510 Participants
|
311 Participants
n=510 Participants
|
311 Participants
n=510 Participants
|
322 Participants
n=510 Participants
|
1266 Participants
n=2040 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
PRIMARY outcome
Timeframe: 2 to 24 hours after procedureIncidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular doppler ultrasound
Outcome measures
| Measure |
Placebo I/Placebo II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I/Placebo II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Placebo I /Nitroglycerin II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I /Nitroglycerin II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
|---|---|---|---|---|
|
Radial Artery Occlusion
|
13 Participants
|
13 Participants
|
10 Participants
|
13 Participants
|
SECONDARY outcome
Timeframe: 30 days after procedureIncidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular doppler ultrasound
Outcome measures
| Measure |
Placebo I/Placebo II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I/Placebo II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Placebo I /Nitroglycerin II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I /Nitroglycerin II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
|---|---|---|---|---|
|
Late Radial Artery Occlusion
|
9 Participants
|
9 Participants
|
7 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: up to 24 hours after procedurePain felt by the patient in the forearm, assessed using numeric pain rating scale ranging from 0 to 10, 0 best (no pain) 10 worst (unbearable pain)
Outcome measures
| Measure |
Placebo I/Placebo II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I/Placebo II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Placebo I /Nitroglycerin II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I /Nitroglycerin II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
|---|---|---|---|---|
|
Pain Assessment
|
2.7 score on a scale
Standard Deviation .42
|
2.4 score on a scale
Standard Deviation .37
|
2.7 score on a scale
Standard Deviation .42
|
2.4 score on a scale
Standard Deviation .37
|
SECONDARY outcome
Timeframe: During the realization of the procedureCatheter friction, as experienced by the operator (subjective measure), during the realization of the procedure
Outcome measures
| Measure |
Placebo I/Placebo II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I/Placebo II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Placebo I /Nitroglycerin II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I /Nitroglycerin II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
|---|---|---|---|---|
|
Spasm (Operator Evaluation)
|
12 Participants
|
10 Participants
|
10 Participants
|
12 Participants
|
SECONDARY outcome
Timeframe: Duration of the procedureTotal duration of the procedure in seconds, from puncture to haemostatic dressing.
Outcome measures
| Measure |
Placebo I/Placebo II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I/Placebo II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Placebo I /Nitroglycerin II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I /Nitroglycerin II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
|---|---|---|---|---|
|
Procedure Duration
|
1,193.22 seconds
Standard Deviation 1,105.82
|
1,216.29 seconds
Standard Deviation 1,179.52
|
1,229.83 seconds
Standard Deviation 1,208.30
|
1,179.67 seconds
Standard Deviation 1,073.80
|
SECONDARY outcome
Timeframe: During the procedureTotal radiation used in the procedure
Outcome measures
| Measure |
Placebo I/Placebo II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I/Placebo II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Placebo I /Nitroglycerin II
n=510 Participants
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I /Nitroglycerin II
n=510 Participants
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
|---|---|---|---|---|
|
Radiation Exposure
|
584.52 mGy
Standard Deviation 497.54
|
591.30 mGy
Standard Deviation 524.38
|
599.78 mGy
Standard Deviation 559.61
|
576.09 mGy
Standard Deviation 457.49
|
Adverse Events
Placebo I/Placebo II
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Nitroglycerin I/Placebo II
Serious events: 0 serious events
Other events: 12 other events
Deaths: 0 deaths
Placebo I /Nitroglycerin II
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Nitroglycerin I /Nitroglycerin II
Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Placebo I/Placebo II
n=510 participants at risk
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I/Placebo II
n=510 participants at risk
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Placebo II: Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Placebo I /Nitroglycerin II
n=510 participants at risk
0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Placebo I: Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
Nitroglycerin I /Nitroglycerin II
n=510 participants at risk
500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
Nitroglycerin I: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
Nitroglycerin II: 500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
|
|---|---|---|---|---|
|
Cardiac disorders
Hypotension
|
1.2%
6/510 • Number of events 6 • 30 days
Hand isquemia
|
2.4%
12/510 • Number of events 12 • 30 days
Hand isquemia
|
1.2%
6/510 • Number of events 6 • 30 days
Hand isquemia
|
2.5%
13/510 • Number of events 13 • 30 days
Hand isquemia
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place